A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...

Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) evaluating the safety, tolerability and preliminary efficacy of ...

Adding metastasis-directed therapy (MDT) to standard of care was tied to improvements in several survival endpoints in oligometastatic prostate cancer, a recent analysis suggests.

Dosimetry data from the Phase 3 ECLIPSE substudy demonstrated favorable organ radiation absorbed doses supporting administration of 7.4 GBq for ...

Actinium-225 is a targeted and highly-potent alpha emitter that holds promise for patients who do not respond to lutetium-177 ...

Docetaxel rechallenge significantly improved survival compared with cabazitaxel in certain men with metastatic ...

In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPC; Real‑world evidence showed Pluvicto achieved longer PFS when init ...

Cancers Symposium, and the updates were full of hope for people with advanced prostate cancer. CURE highlights two studies ...

Median overall survival with olaparib plus abiraterone reached 68 months in mid-stage tria ...

At 7.3 years’ median follow-up, cabazitaxel failed to improve clinical PFS (62.8% vs 67.2%), metastasis-free survival, or overall survival versus androgen deprivation therapy plus radiotherapy.

While some of his allies have lamented that Biden's legacy as president has been reduced to questions of his declining health and mental acuity, many Democrats are still bitter about Biden's 2024 ...